NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Nutriband Inc. Annual Meeting Updates on Board Appointments and AVERSA Fentanyl Development
TL;DR
Nutriband's AVERSA FENTANYL development offers investors a competitive edge through extended patent protection to 2046 and strategic partnerships enhancing market exclusivity.
Nutriband methodically advanced AVERSA FENTANYL through manufacturing scale-up, FDA engagement, patent expansions, and plans for clinical studies leading to an NDA filing.
Nutriband's abuse-deterrent fentanyl patch technology makes the world better by preventing drug misuse and accidental exposure, improving patient safety and public health.
Nutriband's AVERSA technology transforms transdermal patches with abuse-deterrent features, offering an interesting innovation in pharmaceutical safety and drug delivery systems.
Found this article helpful?
Share it with your network and spread the knowledge!
The announcement covers updates from Nutriband's 2026 Annual Shareholders Meeting, focusing on the appointment of two new directors and progress in developing AVERSA™ Fentanyl, an abuse-deterrent fentanyl patch.
Nutriband appointed Alessandro Puddu and Viorica Carlig as new directors during the 2026 Annual Shareholders Meeting held on January 24, 2026.
AVERSA™ is an abuse-deterrent technology that can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
In 2025, Nutriband strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the FDA through a Type C meeting, and advanced branding initiatives for AVERSA™ Fentanyl.
For 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study.
The meeting was held in Orlando, Florida on January 24, 2026.
Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology.
The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB, and the full press release can be viewed at https://ibn.fm/cp5lC.
BioMedWire is a specialized communications platform focusing on Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing wire solutions, article syndication, press release enhancement, social media distribution, and corporate communications solutions through the IBN network.
Curated from InvestorBrandNetwork (IBN)
